Epinephrine Injector

SOL #: SPE2D2-26-R-0009Pre-Solicitation

Overview

Buyer

DEPT OF DEFENSE
Defense Logistics Agency
DLA TROOP SUPPORT
PHILADELPHIA, PA, 19111, United States

Place of Performance

Place of performance not available

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

Drugs And Biologicals (6505)

Set Aside

No set aside specified

Timeline

1
Posted
Apr 29, 2026

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Epinephrine Injectors. This presolicitation notice indicates an upcoming unrestricted and fully competitive acquisition for Epinephrine 0.3 MG/0.3 ML Injection, Auto-Injector 2S in 2 count bottles. The contract aims to establish a national supply source for various federal agencies. The projected solicitation date is August 2026.

Scope of Work

This acquisition will establish a national supply source for Epinephrine Injectors (0.3 MG/0.3 ML, Auto-Injector 2S in 2 count bottles). The resulting contract will provide these items for purchase by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. Annual usage estimates will be detailed in the solicitation's Schedule of Supplies.

Contract & Timeline

  • Type: Firm-Fixed Price, Requirements Type Contract
  • Duration: One-year base period with four one-year options
  • Set-Aside: Unrestricted and Fully Competitive
  • Product Service Code: 6505 (Drugs And Biologicals)
  • Solicitation Method: FAR Part 12 (Commercial Item)
  • Projected Solicitation Date: August 2026 (DLA reserves the right to issue before or after)
  • Published: April 29, 2026

Evaluation

This will be an unrestricted and fully competitive acquisition. All sources may submit a proposal, which shall be considered by the agency. The acquisition will be solicited using FAR Part 12 for commercial items.

Additional Notes

A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Sam.Gov at https://sam.gov. Interested parties should set up automated notifications for updates. For questions, contact Jeremy Brown at (445) 737-5419 or jeremy.brown@dla.mil, or Jason Wray at (445) 737-6304 or Jason.wray@dla.mil.

People

Points of Contact

Jeremy BrownPRIMARY
Jason WraySECONDARY

Files

Files

No files attached to this opportunity

Versions

Version 1Viewing
Pre-Solicitation
Posted: Apr 29, 2026
Epinephrine Injector | GovScope